Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States

NCT04507204 is registered in ClinicalTrials.gov with Purdue Pharma LP as lead sponsor.

NCT NCT04507204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04507204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States
Lead sponsor
Purdue Pharma LP
Phase
Phase 4
Overall status
Terminated
Start date
July 30, 2020
Completion date
January 31, 2022
Enrollment
267 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder